SEC
DYN icon

Seven Eight Capital’s Dyne Therapeutics DYN Stock Holding History

Seven Eight Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-96,934
Closed -$3.48M – 185
2024
Q3 		$3.48M Buy
96,934
+43,195
+80% +$1.72M 0.31% 67
2024
Q2 		$1.9M Buy
53,739
+35,568
+196% +$1.03M 0.2% 151
2024
Q1 		$516K Buy
+18,171
New +$411K 0.05% 449

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Seven Eight Capital's DYN Position: Q4 2024 in Review

Seven Eight Capital sold out of Dyne Therapeutics (DYN) in Q4 2024, closing a stake of 96,934 shares — an estimated $3.48M sold.

Seven Eight Capital first reported a position in DYN in Q1 2024 and held it in 3 quarters. The position peaked at $3.48M in Q3 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q4 2024.

  • Seven Eight Capital reported no remaining Dyne Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 96,934 Dyne Therapeutics shares in Q4 2024, an estimated $3.48M.
  • Seven Eight Capital first reported a position in Dyne Therapeutics in Q1 2024 and held it in 3 quarters.
  • Seven Eight Capital's Dyne Therapeutics position peaked at $3.48M in Q3 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.